Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...

Immunology, filgrastim, epoetin alfa, and insulin glargine were named the slowest growing biosimilar markets, averaging only 26% market share after 5 years. For oncology biosimilars, WAC prices offer ...

Thomas W. LeBlanc, MD, MA, discusses how the COMMANDS study, which compared luspatercept to epoetin alfa in erythropoiesis-stimulating agent (ESA)–naive, transfusion-dependent patients with low-risk ...